Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Lancaster K.E., Mollan K.R., Hanscom B.S., Shook-Sa B.E., Ha T.V., Dumchev K., Djoerban Z., Rose S.M., Latkin C.A., Metzger D.S., Go V.F., Dvoriak S., Reifeis S.A., Piwowar-Manning E.M., Richardson P., Hudgens M.G., Hamilton E.L., Eshleman S.H., Susami H., Chu V.A., Djauzi S., Kiriazova T., Nhan D.T., Burns D.N., Miller W.C., Hoffman I.F.
55503210000;26659057900;6603650318;55990940100;36988527800;8923601900;23472548200;12544917400;57235096800;35944632400;7102536801;57205192774;57193208279;35783326900;57203639655;6603567044;56450237600;7004740977;57202642757;57195576444;23495847800;55757875500;57317058700;7403171278;7406061778;7006682600;
Engaging People Who Inject Drugs Living with HIV in Antiretroviral Treatment and Medication for Opioid Use Disorder: Extended Follow-up of HIV Prevention Trials Network (HPTN) 074
2021
Open Forum Infectious Diseases
8
8
ofab281
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118242331&doi=10.1093%2fofid%2fofab281&partnerID=40&md5=6133eea6e10cff9e76240789c9b5b783
Division of Epidemiology, College of Public Health, Ohio State University, 1841 Neil Ave, 334 Cunz Hall, Columbus, OH 43210-1351, United States; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; UNC Vietnam, Hanoi, Viet Nam; Ukrainian Institute on Public Health Policy, Kyiv, Ukraine; Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Science Facilitation Department, FHI 360, Durham, NC, United States; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States; HIV Prevention Research Division, Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; Academy of Labor, Social Relations and Tourism, Kyiv, Ukraine; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Vietnam Administration of HIV/AIDS Control, Hanoi, Viet Nam; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States; Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Lancaster, K.E., Division of Epidemiology, College of Public Health, Ohio State University, 1841 Neil Ave, 334 Cunz Hall, Columbus, OH 43210-1351, United States; Mollan, K.R., Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Hanscom, B.S., Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Shook-Sa, B.E., Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Ha, T.V., Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, UNC Vietnam, Hanoi, Viet Nam; Dumchev, K., Ukrainian Institute on Public Health Policy, Kyiv, Ukraine; Djoerban, Z., Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Rose, S.M., Science Facilitation Department, FHI 360, Durham, NC, United States; Latkin, C.A., Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States; Metzger, D.S., HIV Prevention Research Division, Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; Go, V.F., Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Dvoriak, S., Academy of Labor, Social Relations and Tourism, Kyiv, Ukraine; Reifeis, S.A., Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Piwowar-Manning, E.M., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Richardson, P., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Hudgens, M.G., Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Hamilton, E.L., Science Facilitation Department, FHI 360, Durham, NC, United States; Eshleman, S.H., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Susami, H., Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Chu, V.A., UNC Vietnam, Hanoi, Viet Nam; Djauzi, S., Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Kiriazova, T., Ukrainian Institute on Public Health Policy, Kyiv, Ukraine; Nhan, D.T., Vietnam Administration of HIV/AIDS Control, Hanoi, Viet Nam; Burns, D.N., Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States; Miller, W.C., Division of Epidemiology, College of Public Health, Ohio State University, 1841 Neil Ave, 334 Cunz Hall, Columbus, OH 43210-1351, United States; Hoffman, I.F., Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Background: People who inject drugs (PWID) living with HIV experience inadequate access to antiretroviral treatment (ART) and medication for opioid use disorders (MOUD). HPTN 074 showed that an integrated intervention increased ART use and viral suppression over 52 weeks. To examine durability of ART, MOUD, and HIV viral suppression, participants could re-enroll for an extended follow-up period, during which standard-of-care (SOC) participants in need of support were offered the intervention. Methods: Participants were recruited from Ukraine, Indonesia and Vietnam and randomly allocated 3:1 to SOC or intervention. Eligibility criteria included: HIV-positive; active injection drug use; 18-60 years of age; ≥1 HIV-uninfected injection partner; and viral load ≥1,000 copies/mL. Re-enrollment was offered to all available intervention and SOC arm participants, and SOC participants in need of support (off-ART or off-MOUD) were offered the intervention. Results: The intervention continuation group re-enrolled 89 participants, and from week 52 to 104, viral suppression (<40 copies/mL) declined from 41% to 29% (estimated 9.4% decrease per year, 95% CI-17.0%;-1.8%). The in need of support group re-enrolled 94 participants and had increased ART (re-enrollment: 55%, week 26: 69%) and MOUD (re-enrollment: 16%, week 26: 25%) use, and viral suppression (re-enrollment: 40%, week 26: 49%). Conclusions: Viral suppression declined in year 2 for those who initially received the HPTN 074 intervention and improved maintenance support is warranted. Viral suppression and MOUD increased among in need participants who received intervention during the study extension. Continued efforts are needed for widespread implementation of this scalable, integrated intervention. © 2021 The Author(s).
antiretroviral therapy; HIV infection; injection drug use; methadone/therapeutic use; viral load
antiretrovirus agent; buprenorphine; methadone; adult; Article; CD4 lymphocyte count; Consolidated Standards of Reporting Trial; controlled study; disease transmission; epidemic; evaluation and follow up; female; health care quality; health education; hepatitis C; human; Human immunodeficiency virus infection; incidence; injection drug user; integrated health care system; intervention study; interview; major clinical study; male; medication compliance; medication for opioid use disorder; medication for opioid use disorder; middle aged; opiate addiction; outcome assessment; paramedical personnel; practice guideline; psychosocial development; randomized controlled trial; telephone interview; viral suppression; virus load; World Health Organization; young adult
Oxford University Press
23288957
Article
Q1
1546
2161

Unit Riset FKUI/Medical Research Unit
Gedung IMERI Tower Riset lt. 9, Jl. Salemba Raya No. 6, Jakarta Pusat, 10430
Telp. : +62 21 29189160 (ext. 201912)
E-mail : manajer.riset.fkui1@gmail.com